blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3471729

EP3471729 - ISOXAZOLMETHYLTHIO-, THIENYLMETHYLTHIO- AND THIAZOMETHYLTHIO-DERIVATIVES FOR USE IN THE TREATMENT OF CANCER; VIRAL INFECTIONS; THROMBOTIC EVENTS OR PLATELET AGGREGATION [Right-click to bookmark this link]
Former [2019/17]THERAPEUTIC COMPOUNDS
[2022/36]
StatusNo opposition filed within time limit
Status updated on  29.12.2023
Database last updated on 23.04.2024
FormerThe patent has been granted
Status updated on  20.01.2023
FormerGrant of patent is intended
Status updated on  24.08.2022
FormerExamination is in progress
Status updated on  03.04.2021
FormerRequest for examination was made
Status updated on  22.03.2019
FormerThe international publication has been made
Status updated on  29.12.2017
Most recent event   Tooltip19.04.2024Lapse of the patent in a contracting state
New state(s): IE		published on 22.05.2024 [2024/21]
Applicant(s)For all designated states
Rutgers, the State University of New Jersey
Old Queens Building
Somerset and George Streets
New Brunswick, NJ 08901 / US
For all designated states
The Curators of the University of Missouri
316 University Hall
Columbia, MO 65211 / US
[2019/17]
Inventor(s)01 / WELSH, William J.
Old Queens
Somerset and George Streets
New Brunswick, New Jersey 08901 / US
02 / BIRGE, Raymond
20 West Street, Apt. 27D
New York, NY 10004 / US
03 / KHOLODOVYCH, Vladyslav
279 White Oak Ridge
Bridgewater, NJ 08807 / US
04 / PENG, Youyi
24 Madison Drive
Plainsboro, NJ 08536 / US
05 / COMOLLO, Thomas Walter
141 Grandview Avenue
West 1-3
Edison, NJ 08837 / US
06 / KIMANI, Stanley G.
132 Sunrise Drive
Edison, NJ 08817 / US
07 / SINGH, Kamlendra
316 University Hall
Columbia, Missouri 65211 / US
 [2019/20]
Former [2019/17]01 / WELSH, William J.
Old Queens
Somerset and George Streets
New Brunswick, New Jersey 08901 / US
02 / BIRGE, Raymond
Old Queens
Somerset and George Streets
New Brunswick, New Jersey 08901 / US
03 / KHOLODOVYCH, Vladyslav
Old Queens
Somerset and George Streets
New Brunswick, New Jersey 08901 / US
04 / PENG, Youyi
Old Queens
Somerset and George Streets
New Brunswick, New Jersey 08901 / US
05 / COMOLLO, Thomas Walter
Old Queens
Somerset and George Streets
New Brunswick, New Jersey 08901 / US
06 / KIMANI, Stanley G.
Old Queens
Somerset and George Streets
New Brunswick, New Jersey 08901 / US
07 / SINGH, Kamlendra
316 University Hall
Columbia, Missouri 65211 / US
Representative(s)Hindles Limited
Clarence House
131-135 George Street
Edinburgh, EH2 4JS / GB
[2019/17]
Application number, filing date17815972.916.06.2017
[2019/17]
WO2017US37895
Priority number, dateUS201662352499P20.06.2016         Original published format: US 201662352499 P
[2019/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017222930
Date:28.12.2017
Language:EN
[2017/52]
Type: A1 Application with search report 
No.:EP3471729
Date:24.04.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 28.12.2017 takes the place of the publication of the European patent application.
[2019/17]
Type: B1 Patent specification 
No.:EP3471729
Date:22.02.2023
Language:EN
[2023/08]
Search report(s)International search report - published on:US28.12.2017
(Supplementary) European search report - dispatched on:EP03.01.2020
ClassificationIPC:A61K31/496, C07C233/64, C07D241/04, A61K31/42, A61P7/02, A61P9/00, A61P31/18, A61P35/00, C07D261/08, C07D295/192, C07D417/14, C07D417/12, C07D413/14, C07D413/12, C07D409/14
[2020/04]
CPC:
C07D417/12 (EP,US); A61K31/4439 (KR); A61K31/42 (EP,US);
A61K31/496 (EP,KR,US); A61K31/506 (KR); A61P31/18 (EP,KR,US);
A61P35/00 (EP,KR,US); A61P7/02 (EP,US); A61P9/00 (EP,US);
A61P9/10 (KR); C07D261/08 (EP,US); C07D295/192 (EP,US);
C07D409/14 (EP,US); C07D413/12 (EP,US); C07D413/14 (EP,US);
C07D417/14 (EP,US); Y02A50/30 (EP) (-)
Former IPC [2019/17]A61K31/496, C07C233/64, C07D241/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/17]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ISOXAZOLMETHYLTHIO-, THIENYLMETHYLTHIO- UND THIAZOMETHYLTHIO-DERIVATE ZUR VERWENDUNG BEI DER BEHANDLUNG VON KREBS, VIRUSINFEKTIONEN, THROMBOTISCHEN EREIGNISSEN ODER BLUTPLÄTTCHENAGGREGATION[2022/36]
English:ISOXAZOLMETHYLTHIO-, THIENYLMETHYLTHIO- AND THIAZOMETHYLTHIO-DERIVATIVES FOR USE IN THE TREATMENT OF CANCER; VIRAL INFECTIONS; THROMBOTIC EVENTS OR PLATELET AGGREGATION[2022/36]
French:DÉRIVÉS D'ISOXAZOLMÉTHYLTHIO, DE THIÉNYLMÉTHYLTHIO ET DE THIAZOMÉTHYLTHIO DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER, DES INFECTIONS VIRALES, DES ÉVÉNEMENTS THROMBOTIQUES OU DE L'AGRÉGATION PLAQUETTAIRE[2022/36]
Former [2019/17]THERAPEUTISCHE VERBINDUNGEN
Former [2019/17]THERAPEUTIC COMPOUNDS
Former [2019/17]COMPOSÉS THÉRAPEUTIQUES
Entry into regional phase18.01.2019National basic fee paid 
18.01.2019Search fee paid 
18.01.2019Designation fee(s) paid 
18.01.2019Examination fee paid 
Examination proceduredeletedDate on which the examining division has become responsible
18.01.2019Examination requested  [2019/17]
30.07.2020Amendment by applicant (claims and/or description)
08.04.2021Despatch of a communication from the examining division (Time limit: M06)
18.10.2021Reply to a communication from the examining division
04.02.2022Despatch of a communication from the examining division (Time limit: M04)
13.06.2022Reply to a communication from the examining division
25.08.2022Communication of intention to grant the patent
04.01.2023Fee for grant paid
04.01.2023Fee for publishing/printing paid
04.01.2023Receipt of the translation of the claim(s)
Opposition(s)23.11.2023No opposition filed within time limit [2024/05]
Fees paidRenewal fee
27.06.2019Renewal fee patent year 03
15.06.2020Renewal fee patent year 04
14.06.2021Renewal fee patent year 05
13.05.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT22.02.2023
CZ22.02.2023
DK22.02.2023
EE22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
MC22.02.2023
NL22.02.2023
PL22.02.2023
RO22.02.2023
RS22.02.2023
SE22.02.2023
SI22.02.2023
SK22.02.2023
SM22.02.2023
NO22.05.2023
GR23.05.2023
IE16.06.2023
LU16.06.2023
IS22.06.2023
PT22.06.2023
[2024/21]
Former [2024/15]AT22.02.2023
CZ22.02.2023
DK22.02.2023
EE22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
MC22.02.2023
NL22.02.2023
PL22.02.2023
RO22.02.2023
RS22.02.2023
SE22.02.2023
SI22.02.2023
SK22.02.2023
SM22.02.2023
NO22.05.2023
GR23.05.2023
LU16.06.2023
IS22.06.2023
PT22.06.2023
Former [2024/11]AT22.02.2023
CZ22.02.2023
DK22.02.2023
EE22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
MC22.02.2023
NL22.02.2023
PL22.02.2023
RO22.02.2023
RS22.02.2023
SE22.02.2023
SI22.02.2023
SK22.02.2023
SM22.02.2023
NO22.05.2023
GR23.05.2023
IS22.06.2023
PT22.06.2023
Former [2024/09]AT22.02.2023
CZ22.02.2023
DK22.02.2023
EE22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
MC22.02.2023
NL22.02.2023
PL22.02.2023
RO22.02.2023
RS22.02.2023
SE22.02.2023
SK22.02.2023
SM22.02.2023
NO22.05.2023
GR23.05.2023
IS22.06.2023
PT22.06.2023
Former [2023/50]AT22.02.2023
CZ22.02.2023
DK22.02.2023
EE22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
NL22.02.2023
PL22.02.2023
RO22.02.2023
RS22.02.2023
SE22.02.2023
SK22.02.2023
SM22.02.2023
NO22.05.2023
GR23.05.2023
IS22.06.2023
PT22.06.2023
Former [2023/49]AT22.02.2023
CZ22.02.2023
DK22.02.2023
EE22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
NL22.02.2023
PL22.02.2023
RO22.02.2023
RS22.02.2023
SE22.02.2023
SM22.02.2023
NO22.05.2023
GR23.05.2023
IS22.06.2023
PT22.06.2023
Former [2023/48]AT22.02.2023
DK22.02.2023
EE22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
NL22.02.2023
PL22.02.2023
RS22.02.2023
SE22.02.2023
SM22.02.2023
NO22.05.2023
GR23.05.2023
IS22.06.2023
PT22.06.2023
Former [2023/46]AT22.02.2023
DK22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
NL22.02.2023
PL22.02.2023
RS22.02.2023
SE22.02.2023
SM22.02.2023
NO22.05.2023
GR23.05.2023
IS22.06.2023
PT22.06.2023
Former [2023/39]AT22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
NL22.02.2023
PL22.02.2023
RS22.02.2023
SE22.02.2023
NO22.05.2023
GR23.05.2023
IS22.06.2023
PT22.06.2023
Former [2023/38]AT22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
NL22.02.2023
PL22.02.2023
RS22.02.2023
SE22.02.2023
NO22.05.2023
GR23.05.2023
PT22.06.2023
Former [2023/37]AT22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
NL22.02.2023
RS22.02.2023
SE22.02.2023
NO22.05.2023
GR23.05.2023
PT22.06.2023
Former [2023/36]AT22.02.2023
ES22.02.2023
FI22.02.2023
HR22.02.2023
LT22.02.2023
LV22.02.2023
NL22.02.2023
RS22.02.2023
SE22.02.2023
NO22.05.2023
PT22.06.2023
Former [2023/35]AT22.02.2023
ES22.02.2023
HR22.02.2023
LT22.02.2023
NL22.02.2023
RS22.02.2023
NO22.05.2023
PT22.06.2023
Former [2023/34]ES22.02.2023
LT22.02.2023
RS22.02.2023
PT22.06.2023
Former [2023/33]ES22.02.2023
LT22.02.2023
Documents cited:Search   [ ] - No further relevant documents disclosed
International search[A]US3987179  (NADELSON JEFFREY) [A] 1-10, 17, 31, 32, 37-44, 49- 55, 77, 78 * Col 1, In 4-8; Col 1, In 10-24; Col 1, In 50-51 *;
 [A]US2004266840  (SINGH RAJINDER [US], et al) [A] 1-10, 17, 31, 32, 37-44, 49- 55, 77, 78 * abstract; para [0568], Table 1 *;
 [A]US2010184766  (KUNZER AARON R [US], et al) [A] 1-10, 17, 31, 32, 37-44, 49- 55, 77, 78* para [0173];[0174]; [0283] *;
 [A]US2014128410  (CAI XIONG [US], et al) [A] 1-10, 17, 31, 32, 37-44, 49- 55, 77, 78 * para [0068];[0069]; pg 7, Table A *;
 [A]  - PUBCHEM, (20050710), Database accession no. 1124072, XP055448934 [A] 1-10, 17, 31, 32, 37-44, 49- 55, 77, 78 * pg. 1-12. pg 3; pg 11 *
by applicantUS4559157
 US4608392
 US4820508
 US4938949
 US4992478
    - GRAHAM D.K. et al., Nature reviews Cancer, (20141200), vol. 14, no. 12, pages 769 - 785
    - LEMKE G., Biology of the TAM receptors, (20131100), vol. 5, no. 11, page a009076
    - VERMA A. et al., Molecular cancer therapeutics, (20111000), vol. 10, no. 10, pages 1763 - 1773
    - ROTHLIN C.V. et al., Annual review of immunology, (20150000), vol. 33, pages 355 - 391
    - ROTHLIN C.V. et al., Cell, (20071214), vol. 131, no. 6, pages 1124 - 113
    - LU Q.LEMKE G., Science, (20010713), vol. 293, no. 5528, pages 306 - 311
    - GRAHAM D.K., Nature reviews Cancer
    - FLEISHER, D. et al., "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews, (19960000), vol. 19, doi:10.1016/0169-409X(95)00103-E, page 115, XP002478093

DOI:   http://dx.doi.org/10.1016/0169-409X(95)00103-E
    - J. Med. Chem., (19960000), vol. 39, page 10
    - Methods in Enzymology, Academic Press, (19850000), vol. 42, pages 309 - 396
    - "Design and Application of Prodrugs", H. BUNDGAARD, A Textbook of Drug Design and Development, (19910000), pages 113 - 191
    - H. BUNDGAARD, Advanced Drug Delivery Reviews, (19920000), vol. 8, pages 1 - 38
    - H. BUNDGAARD et al., Journal of Pharmaceutical Sciences, (19880000), vol. 77, page 285
    - N. KAKEYA et al., Chem. Pharm. Bull., (19840000), vol. 32, page 692
    - BERGE, S. M. et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, (19770000), vol. 66, doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - SASAKI T et al., The EMBO Journal, (20060111), vol. 25, no. 1, pages 80 - 87
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.